Health Care • Medical/Dental Instruments
$82.91 ▲ +1.65
(+2.03%)
MKT CAP: $11.13B • VOL: 862.0K
52W L $60 52W H $101
GMED // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $2.94B | $2.52B | $1.57B |
| YoY Revenue Growth % | +16.7% | +60.6% | — |
| Gross Profit | $1.98B | $1.48B | $690.1M |
| Gross Margin % | 67.4% | 58.9% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $479.8M | $166.0M | $133.1M |
| Operating Margin % | 16.3% | 6.6% | 8.5% |
| Net Income (GAAP) | $537.9M | $103.0M | $122.9M |
| EBITDA (Normalized) | $611.6M | $258.3M | $189.6M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $753.4M | $520.6M | $243.5M |
| Capital Expenditures (CapEx) | $164.7M | $115.4M | $70.6M |
| Free Cash Flow (FCF) | $588.8M | $405.2M | $172.9M |
| FCF Margin % | 20.0% | 16.1% | 11.0% |
| Return on Invested Capital (ROIC %) | 8.7% | 3.4% | 2.8% |
| Cash & Short-Term Equivalents | $526.2M | $784.4M | $673.5M |
| Total Debt (Short + Long Term) | $328.3M | $483.5M | $1.43B |
| Total Stockholders' Equity | $4.57B | $4.18B | $2.94B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GMED.